San Diego—For the treatment of Crohn’s disease, the combination of two monoclonal antibodies targeting different inflammatory mediators plus methotrexate was found to be active and reasonably well tolerated after 26 weeks in an interim analysis of an ongoing phase 4 study.
The alpha4beta7 integrin receptor antagonist vedolizumab (Entyvio, Takeda) and the tumor necrosis factor inhibitor adalimumab (Humira, AbbVie) were combined with methotrexate in biologic-naive patients considered